NEXIEN BIOPHARMA, INC.: 10-Q filed 2023-02-08

Name: NEXIEN BIOPHARMA, INC.: 10-Q filed 2023-02-08
Creator: NEXIEN BIOPHARMA, INC.

What NEXIEN BIOPHARMA, INC. reported in its quarterly report filed 2023-02-08 (fiscal Q2 2023): 16 published measures, 49 facts as tagged in accession 0001493152-23-003903.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-02-08
Fiscal period: fiscal Q2 2023
Accession: 0001493152-23-003903 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NEXIEN BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-12-31	76,971	USD
At 2022-06-30	124,518	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-12-31	279,292	USD
At 2022-06-30	242,123	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-12-31	-202,321	USD
At 2022-09-30	-160,604	USD
At 2022-06-30	-117,605	USD
At 2021-12-31	-62,425	USD
At 2021-09-30	-39,986	USD
At 2021-06-30	-13,775	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-10-01 to 2022-12-31	-93,592	USD	92
2022-07-01 to 2022-12-31	-188,466	USD	184
2022-07-01 to 2022-09-30	-94,874	USD	92
2021-10-01 to 2021-12-31	-220,194	USD	92
2021-07-01 to 2021-12-31	-341,905	USD	184
2021-07-01 to 2021-09-30	-121,711	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-07-01 to 2022-12-31	-47,907	USD	184
2021-07-01 to 2021-12-31	-30,099	USD	184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2021-07-01 to 2021-12-31	15,000	USD	184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-12-31	-11,121,924	USD
At 2022-06-30	-10,933,458	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-10-01 to 2022-12-31	61,915,053	shares	92
2022-07-01 to 2022-12-31	61,493,507	shares	184
2021-10-01 to 2021-12-31	56,211,756	shares	92
2021-07-01 to 2021-12-31	55,990,775	shares	184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-10-01 to 2022-12-31	0	USD/shares	92
2022-07-01 to 2022-12-31	0	USD/shares	184
2021-10-01 to 2021-12-31	-0.004	USD/shares	92
2021-07-01 to 2021-12-31	-0.01	USD/shares	184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-12-31	76,971	USD
At 2022-06-30	124,518	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-12-31	279,292	USD
At 2022-06-30	242,123	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-10-01 to 2022-12-31	73,032	USD	92
2022-07-01 to 2022-12-31	147,347	USD	184
2021-10-01 to 2021-12-31	213,496	USD	92
2021-07-01 to 2021-12-31	328,435	USD	184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-12-31	62,022,196	shares
At 2022-06-30	60,522,196	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-12-31	10,862,651	USD
At 2022-06-30	10,759,051	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-10-01 to 2022-12-31	66,872	USD	92
2022-07-01 to 2022-12-31	125,927	USD	184
2021-10-01 to 2021-12-31	202,056	USD	92
2021-07-01 to 2021-12-31	310,955	USD	184

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2022-10-01 to 2022-12-31	-20,560	USD	92
2022-07-01 to 2022-12-31	-41,119	USD	184
2021-10-01 to 2021-12-31	-6,698	USD	92
2021-07-01 to 2021-12-31	-13,470	USD	184

Inspect the source

Entity: NEXIEN BIOPHARMA, INC. / CIK 0001625288
Captured: 2026-09-21T17:21:50.748Z
SEC response SHA-256: 044a00232373cfad706e13d40a0fcc524943f52c3deb14bbc85e1072ff58fe5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001625288.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))